Questions Remain For Samsung Bioepis Post-Biogen
Management Changes, Strategic Focus And Structural Aspects Yet To Be Decided
In exclusive comments made to Generics Bulletin, Samsung Biologics has acknowledged that it has yet to decide on several aspects of Samsung Bioepis’ management, structure and strategic focus once Biogen completes the sale of its stake in the biosimilars joint venture to its partner.
